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Abstract The term ‘‘familial male breast cancer’’ is often
misleading, because in the breast cancer families reported
in the literature, the vast majority of the patients were
women and only a few were men. In this report, we present
the rare case of a strictly defined familial male breast
cancer (MBC) in which exclusively men were diagnosed
with breast cancer. Three of four brothers developed the
disease between the age of 46 and 64 years within a period
of 21 years whereas all female relatives remained unaf-
fected. The three affected men did not show the typical
known clinical and genetic risk factors for MBC. An
X-linked recessive inheritance may be possible in these
cases. One way to potentially improve the identification of
the causes of MBC could be a through a strictly studying
families in which the male members were exclusively
diagnosed with this malignancy. This approach emphasizes
familial MBC as a distinct entity and not only as a variant
of female breast cancer.
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Introduction
Breast cancer in men is rare. The incidence is approxi-
mately 1% of that in women. Causes of male breast cancer
are incompletely characterized and understood. Neverthe-
less, there is a definite association with family history and
genetic factors [1–5]. In order to expose the influence of
genetics on the disease, affected families were analyzed in
detail and terms such as ‘‘male breast cancer families’’
[6–10] or ‘‘familial male breast cancer’’ [11–16] were
introduced into the literature. These terms, however, are
often misleading, because in the analyzed breast cancer
families, the vast majority of the patients were women and
only a few were men [11, 12, 14, 15]. We would prefer to
narrow the definition of ‘‘familial male breast cancer’’ and
use this term only for families in which exclusively male
members are affected. In this report, we present the rare case
of such a strictly defined ‘‘familial male breast cancer’’.
Case studies
We report the clinicopathologic, treatment and outcome
characteristics of three brothers with familial breast cancer.
These features, including the results of genetic testing of
two of the men, are summarized in Table 1. Tumor stage
was reported according to the current American Joint
Committee on Cancer (AJCC)/International Union Against
Cancer (UICC) TNM guidelines [17, 18]. Furthermore, we
present on the basis of the pedigree important features of
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the family history. All individuals tested for BRCA1/2
mutations gave signed informed consent.
Case 1
In 1982, at the age of 46, the oldest brother of the presented
family was diagnosed with invasive ductal carcinoma in
the central region of the right breast (stage IIA: pT1c pN1a
[2/11] cM0; moderately differentiated grading [G2], hor-
monal receptor [HR] status: estrogen receptor [ER] posi-
tive, progesterone receptor [PR] positive, HER-2/neu
negative). The patient’s history was, with the exception of
hepatitis B, unremarkable. The body mass index (BMI) was
28. He was surgically treated with breast-conserving ther-
apy and axillary lymph node dissection. A standard adju-
vant breast radiation was performed; systemic treatment
was not recommended. In the subsequent years, with regard
to breast cancer, he remained disease-free.
In 2002, the patient was diagnosed with acute myelo-
genic leukemia (AML) (French-American-British classifi-
cation type M5a). With induction chemotherapy, a
complete remission could be achieved. Prior to the inten-
ded allogeneic stem cell transplantation, however, he
experienced a relapse. In 2003, 8 months after the initial
diagnosis of AML, he died at the age of 67 of this disease.
Survival time after initial diagnosis of breast cancer was
250 months.
Case 2
In 1995, at the age of 57, the second oldest brother of the
family observed sanguineous discharge from the right
nipple. Further diagnostic testing revealed a retromamillary
lesion. After confirming a moderately differentiated inva-
sive ductal carcinoma by core biopsy, the patient received a
mastectomy and axillary lymph node dissection. According
to the then valid guidelines for TNM stage I disease (pT1c
pN0 [0/20] cM0; G2, ER/PR unknown, HER-2/neu
unknown), he received neither postoperative radiotherapy
nor adjuvant systemic treatment. The patient’s preoperative
history was unremarkable. The BMI was 27.
As of July 2010, at 185 months of follow up, the patient
was still disease-free. No other malignancy has been found
to this point.
Case 3
The third oldest brother of the family presented in 2003 at
the age of 64 with a breast lump which was located in the
left retromamillary region. Core biopsy revealed a mod-
erately differentiated ductal invasive carcinoma and
lumpectomy with axillary lymph node dissection was
performed. For TNM stage I (pT1c pN0 [0/16] cM0; G2,
ER positive, PR negative, HER-2/neu negative) disease,
postoperative radiation was performed. The recommended
Table 1 Summary of characteristics of three brothers with familial male breast cancer
Case 1 Case 2 Case 3
Year of diagnosis 1982 1995 2003
Age at initial diagnosis 46 57 64
TNM classification (stage)a pT1c pN1 cM0 (IIA) pT1c pN0 cM0 (I) pT1c pN0 cM0 (I)
Histological type Ductal Ductal Ductal
Grading G2 G2 G2
Hormone receptor-status ER? PR? Unknown ER? PR-
HER-2/neu status Negative Unknown Negative
Genetic findings
BRCA1 Not done Negative Negative
BRCA2 Not done Negative Negative
TP53 Not done Not done Negative
Kind of surgery BCT ? ALD Mastectomy ? ALD BCT ? ALD
Adjuvant systemic treatment No No No
Postoperative radiotherapy Yes No Yes
Status Dead (leukemia) Alive, NED Alive, NED
Age at the last follow-up, in living patients in July 2010 67 72 71
Breast cancer-specific survival (months) 250 185 81
ER Estrogen receptor, PR Progesterone receptor, BCT Breast-conserving therapy, ALD Axillary lymph node dissection
NED No evidence for disease
a AJCC (American Joint Committee on Cancer)/UICC (International Union Against Cancer) TNM Classification
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endocrine therapy with tamoxifen was declined by the
patient. The preoperative history was unremarkable. The
BMI was 25.
As of July 2010, at 81 months of follow up, the patient
was still disease-free. No other malignancy has been found
to this point.
Pedigree (Fig. 1)
The three male breast cancer patients have three other
siblings. The youngest brother of the family remained up
until now unaffected from breast cancer or other malig-
nancies. In 2004, at the age of 64, a palpable lesion was
surgically removed from the right breast; pathological
examination showed a benign finding (dermoid cyst). Two
sisters, today 67 and 68 years old, also remained unaf-
fected from breast cancer at last contact. In the history of
these three siblings, there were no hereditary or malignant
diseases. The same holds true for the ancestry and the
following generation. The father of the three men and a
paternal uncle remained unaffected from breast cancer or
other malignancies, like all the female family members (the
mother of the brothers, and two aunts). For the deceased
individuals, cardiovascular disease was the cause of the
death.
Four siblings of the family (two of the breast cancer
affected brothers, the unaffected brother and one sister)
have all together 10 offspring. The medical histories of the
nine females and one male individual are unremarkable to
date.
Genetic testing
The BRCAPRO 5.0 model [19], which is considered to be
a very useful tool for predicting BRCA1- and especially
BRCA2-mutations in male breast cancer patients [20]
calculated a mutation probability of 0.00 for the presence
of a BRCA1-, but one of 0.982 for that of a BRCA2
mutation. However, no mutation in both genes could by
identified by two independent laboratories. The exons of
the BRCA1- and BRCA2-gene and the neighbouring
sequences of the introns were analyzed after PCR ampli-
fication. In addition, a MLPA—(Multiplex Ligation-
dependent Probe Amplification) analysis has been used
(SALSA MLPA kits BRCA1 P002-C1 and BRCA2 P090-
A2; MCR Holland). A germline TP53-mutation was also
excluded in case 3 by sequencing its exons.
Discussion
In this report, we present the rare case of a strictly defined
‘‘familial male breast cancer’’ in which exclusively men
were diagnosed with breast cancer. Three of four brothers
developed the disease between the age of 46 and 64 years
within a period of 21 years whereas all female relatives
remained unaffected. Remarkably, the three affected men
did not show the typical known clinical and genetic risk
factors for MBC. Two of these men have children.
Both genetic and lifestyle/environmental factors have
been implicated in the etiology of breast cancer, which is a
Fig. 1 Family pedigree. Br Breast cancer, Leu Leukemia, First number Current age or age at death, Second number Age at breast cancer
diagnosis
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heterogeneous disease. As with cancer of the female breast,
the causes of male breast cancer (MBC) are incompletely
characterized and understood. Nevertheless, there is a
definite association with family history and genetic factors
[1–5]. Approximately 15% to 20% of men with breast
cancer report a family history of breast or ovarian cancer
[3]. Only a few genes having high penetrance mutations
have been shown to be involved in the etiology of MBC.
BRCA2 is the most clearly associated gene mutation [1–3];
in some families with BRCA2-mutations, multiple affected
male relatives had been observed [6]. In the reported
family, however, a mutation of this gene could not be
found. Further associations have been suggested for
BRCA1, PTEN, P53, and CHEK2 [1–3]. The presence of
other high penetrance germ line mutations of other genes
suggested were to be involved in the pathogenesis of MBC,
such as BRCA1 and TP53 mutations found in the Li-Fra-
umeni cancer syndrome, as well as PTEN mutations typical
for the Cowden syndrome or STK11/LKB1 mutations as
observed in the Peutz-Jeghers syndrome could be excluded
by genetic analysis (BRCA1 and TP53) or on grounds of
clinical and familial features. No MBC was observed in the
families with pathogenic mutations of the RAD51C gene
[21]. The CHEK2 1100delC variant, not analyzed in this
study, is unlikely to account for a significant fraction of
MBC [22–25]. PALB2 was found to be a breast cancer
predisposition gene [26]. Several pedigrees reported in the
literature to carry protein-truncating PALB2 mutations also
contained MBC patients. The study of Sauty de Chalon
et al., which included 25 MBC cases of such families,
however, provided no evidence that germline PALB2
mutations are associated with an increased risk of MBC
[27].
The fact that only males are affected in a family is
typical for X-linked recessive inheritance even if some
women occasionally manifest features of an X-linked
recessive trait. No high or moderate- to low penetrance
gene associated only with breast cancer, however, have
been identified on the X-chromosome so far [28].
Hormonal levels, particularly increased circulating
estradiol levels and disturbed estrogen/testosterone ratio,
may contribute to an increased risk of the disease [1–3].
Increased estradiol levels might be caused by factors such
as cirrhosis of the liver, obesity and exogenous estrogen.
Furthermore, testicular abnormalities such as undescended
testes, congenital inguinal hernia, orchiectomy, orchitis,
and infertility were reported to be risk factors for MBC
[1–3]. None of our three MBC patients had the above
mentioned conditions or testicular problems, and all except
one of the brothers of the family had children. Furthermore,
recognized risk factors such as Klinefelter’s syndrome or
androgen hyposensitivity (Reifenstein’s syndrome) can be
clearly excluded in the presented family, due to a lack of
the distinct and clinically easily recognizable features
which are associated with these disorders. It has been
reported that working in hot environments might enhance
the risk for male breast cancer, possibly because long-
lasting exposure to high ambient temperature can lead to
testicular failure [1]. One of the three brothers (case 2)
worked for many years with furnaces in the ceramic
industry.
Several authors evaluated oncogenic influences on the
breast during fetal life and infancy [29, 30]. In our reported
cases, it is notable that the three breast cancer affected
brothers were born before World War II (born in 1936, 1937
and 1938); the three unaffected siblings, however, were born
during the war (born in 1940, 1943 and 1944). It is certain
that the older brothers were exposed to different nutritional
situations both in utero and in early infancy compared to the
three siblings who were born in an environment of war-time
insufficiencies. These influences cannot be completely ret-
rospectively confirmed today; a gene-environment interac-
tion, however, may be hypothesized.
The available data on MBC arise from small studies
involving few patients often belonging to a small geo-
graphic area. Larger MBC cohorts should therefore be
collected for candidate gene, genome-wide association
studies (GWAS) or for the analysis of gene-environment
interactions. One way to potentially improve the identifi-
cation of the causes of MBC could be a through a strictly
studying families in which the male members were
exclusively diagnosed with this malignancy. This approach
emphasizes familial MBC as a distinct entity [2, 3] and not
only as a variant of female breast cancer.
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